Neuren submits IND & first patients complete Phase 2 trials

Neuren Pharmaceuticals Limited (ASX: NEU) announced the submission of an Investigational New Drug (IND) request for NNZ-2591 in Prader-Willi syndrome. The company gives updates on its continuing Phase 2 clinical trials for each of the Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. The company’s drug NNZ-2591 is developed for four severe neurological disorders that develop in early childhood and for which no approved medicines are available.

The application was submitted to the United States Food and Drug Administration on 22 December for consent to advance with a Phase 2 trial in Prader-Willi syndrome. The clinical trials continue in the other three syndromes, the first trials of NNZ-2591 in children with each syndrome.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com